Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XLO
DateTimeSourceHeadlineSymbolCompany
19/12/202423:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
19/12/202423:30GlobeNewswire Inc.Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GIĀ NASDAQ:XLOXilio Therapeutics Inc
16/12/202423:30GlobeNewswire Inc.Xilio Therapeutics Appoints Caroline Hensley as Chief Legal OfficerNASDAQ:XLOXilio Therapeutics Inc
04/12/202408:30GlobeNewswire Inc.Xilio Therapeutics Announces Inducement Grants UnderĀ Nasdaq Listing Rule 5635(c)(4)NASDAQ:XLOXilio Therapeutics Inc
08/11/202401:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
08/11/202401:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
08/11/202401:15GlobeNewswire Inc.Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
08/11/202401:05GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024Ā Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
31/10/202400:01GlobeNewswire Inc.Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
04/10/202423:05GlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
03/10/202407:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
03/10/202406:15GlobeNewswire Inc.Xilio Therapeutics Announces Inducement Grants UnderĀ Nasdaq Listing Rule 5635(c)(4)NASDAQ:XLOXilio Therapeutics Inc
28/09/202411:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
28/09/202411:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
28/09/202411:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
28/09/202411:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
28/09/202411:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
28/09/202411:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
28/09/202411:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
28/09/202411:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
14/09/202406:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
29/08/202406:01GlobeNewswire Inc.Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:XLOXilio Therapeutics Inc
08/08/202421:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
08/08/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
08/08/202421:30GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
07/08/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
18/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
18/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
18/06/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
14/06/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XLO